212 related articles for article (PubMed ID: 26453552)
1. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
[TBL] [Abstract][Full Text] [Related]
2. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
Nasr RR; Hmadi RA; El-Eit RM; Iskandarani AN; Jabbour MN; Zaatari GS; Mahon FX; Pisano CC; Darwiche ND
Int J Cancer; 2015 Aug; 137(3):698-709. PubMed ID: 25557649
[TBL] [Abstract][Full Text] [Related]
3. The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism.
Di Francesco AM; Meco D; Torella AR; Barone G; D'Incalci M; Pisano C; Carminati P; Riccardi R
Biochem Pharmacol; 2007 Mar; 73(5):643-55. PubMed ID: 17150196
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the retinoid-related molecules (E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways.
Parrella E; Giannì M; Fratelli M; Barzago MM; Raska I; Diomede L; Kurosaki M; Pisano C; Carminati P; Merlini L; Dallavalle S; Tavecchio M; Rochette-Egly C; Terao M; Garattini E
Mol Pharmacol; 2006 Sep; 70(3):909-24. PubMed ID: 16788091
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma.
El Hajj H; Khalil B; Ghandour B; Nasr R; Shahine S; Ghantous A; Abdel-Samad R; Sinjab A; Hasegawa H; Jabbour M; Hall WW; Zaatari G; Dbaibo G; Pisano C; Bazarbachi A; Darwiche N
Blood; 2014 Sep; 124(13):2072-80. PubMed ID: 25035162
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models.
Karam L; Houshaymi B; Abdel-Samad R; Jaafar M; Halloum I; Pisano C; Neipel F; Darwiche N; Abou Merhi R
Oncol Rep; 2018 Feb; 39(2):721-730. PubMed ID: 29207182
[TBL] [Abstract][Full Text] [Related]
7. The synthetic retinoid ST1926 attenuates prostate cancer growth and potentially targets prostate cancer stem-like cells.
Bahmad HF; Samman H; Monzer A; Hadadeh O; Cheaito K; Abdel-Samad R; Hayar B; Pisano C; Msheik H; Liu YN; Darwiche N; Abou-Kheir W
Mol Carcinog; 2019 Jul; 58(7):1208-1220. PubMed ID: 30883933
[TBL] [Abstract][Full Text] [Related]
8. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
Zanchi C; Zuco V; Lanzi C; Supino R; Zunino F
Cancer Res; 2005 Mar; 65(6):2364-72. PubMed ID: 15781651
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activities of the synthetic retinoid ST1926 in two-dimensional and three-dimensional human breast cancer models.
Aouad P; Saikali M; Abdel-Samad R; Fostok S; El-Houjeiri L; Pisano C; Talhouk R; Darwiche N
Anticancer Drugs; 2017 Aug; 28(7):757-770. PubMed ID: 28471809
[TBL] [Abstract][Full Text] [Related]
10. Cellular and pharmacological bases of the antitumor activity of a novel adamantyl retinoid, ST1926.
Pisano C; Merlini L; Penco S; Carminati P; Zunino F
J Chemother; 2004 Nov; 16 Suppl 4():74-6. PubMed ID: 15688616
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.
Zuco V; Benedetti V; De Cesare M; Zunino F
Int J Cancer; 2010 Mar; 126(5):1246-55. PubMed ID: 19676051
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
Zuco V; Zanchi C; Cassinelli G; Lanzi C; Supino R; Pisano C; Zanier R; Giordano V; Garattini E; Zunino F
Cell Death Differ; 2004 Mar; 11(3):280-9. PubMed ID: 14657960
[TBL] [Abstract][Full Text] [Related]
13. Resistance to the atypical retinoid ST1926 in SK-N-AS cells selected the subline rAS-ST with enhanced sensitivity to ATRA mediated by not conventional mechanisms: DNA damage, G2 accumulation and late telomerase inhibition.
Di Francesco AM; Cusano G; Franzese O; Orienti I; Falconi M; Vesci L; Riccardi R
Toxicol In Vitro; 2015 Oct; 29(7):1628-38. PubMed ID: 26096597
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
15. New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: the role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome.
Fratelli M; Fisher JN; Paroni G; Di Francesco AM; Pierri F; Pisano C; Godl K; Marx S; Tebbe A; Valli C; Gianni M; Stravalaci M; Gobbi M; Terao M; Garattini E
Eur J Cancer; 2013 Apr; 49(6):1491-500. PubMed ID: 23245330
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice.
El-Houjeiri L; Saad W; Hayar B; Aouad P; Tawil N; Abdel-Samad R; Hleihel R; Hamie M; Mancinelli A; Pisano C; El Hajj H; Darwiche N
Mol Cancer Ther; 2017 Oct; 16(10):2047-2057. PubMed ID: 28619754
[TBL] [Abstract][Full Text] [Related]
17. A novel atypical retinoid endowed with proapoptotic and antitumor activity.
Cincinelli R; Dallavalle S; Merlini L; Penco S; Pisano C; Carminati P; Giannini G; Vesci L; Gaetano C; Illy B; Zuco V; Supino R; Zunino F
J Med Chem; 2003 Mar; 46(6):909-12. PubMed ID: 12620066
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
[TBL] [Abstract][Full Text] [Related]
19. Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response.
Zuco V; Zanchi C; Lanzi C; Beretta GL; Supino R; Pisano C; Barbarino M; Zanier R; Bucci F; Aulicino C; Carminati P; Zunino F
Neoplasia; 2005 Jul; 7(7):667-77. PubMed ID: 16026646
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
